Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients-Reference-Cited by-同舟云学术

Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients

Published:2019-11 Issue:11 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Boidin Clément¹²,Bourguignon Laurent¹²³,Cohen Sabine⁴,Roger Claire⁵⁶,Lefrant Jean-Yves⁵⁶,Roberts Jason A.⁷⁸^ORCID,Allaouchiche Bernard⁹¹⁰¹¹,Lepape Alain⁹¹²,Friggeri Arnaud⁹¹¹¹²,Goutelle Sylvain¹²³^ORCID

Affiliation:

1. Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie, Lyon, France

2. UMR CNRS 5558, Laboratoire de Biométrie et Biologie Évolutive, Villeurbanne, France

3. Université de Lyon, Université Claude Bernard Lyon 1, ISPB—Faculté de Pharmacie de Lyon, Lyon, France

4. Hospices Civils de Lyon, Groupement Hospitalier Sud, Laboratoire de Pharmaco-Toxicologie, Pierre-Bénite, France

5. Centre Hospitalier Universitaire de Nîmes, Service de Réanimation, Nîmes, France

6. Université de Montpelier, Faculté de Médecine de Nîmes, EA 2992, Dysfonctions des Interfaces Vasculaires, Nîmes, France

7. Departments of Intensive Care Medicine and Pharmacy, Royal Brisbane and Women’s Hospital, Brisbane, Australia

8. Centre for Clinical Research and School of Pharmacy, The University of Queensland, Brisbane, Australia

9. Hospices Civils de Lyon, Groupement Hospitalier Sud, Service d’Anesthésie et de Réanimation, Lyon, France

10. Université de Lyon, VetAgro Sup, Équipe APSCe: Agressions Pulmonaires et Circulatoires dans le Sepsis, Marcy l’Etoile, France

11. Faculté de Médecine Lyon Sud-Charles Mérieux, Université de Lyon, Université Claude Bernard Lyon 1, Oullins, France

12. UMR CNRS 5308, Inserm U1111, Centre International de Recherche en Infectiologie, Laboratoire des Pathogènes Émergents, Lyon, France

Abstract

Amikacin is commonly used for probabilistic antimicrobial therapy in critically ill patients with sepsis. Its narrow therapeutic margin makes it challenging to determine the right individual dose that ensures the highest efficacy target attainment rate (TAR) in this setting. This study aims to develop a new initial dosing approach for amikacin by optimizing the a priori TAR in this population.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00993-19

Reference49 articles.

1. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis*

2. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study

3. Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria

4. Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally

5. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative assessment of trough and peak levels and AUC24 for amikacin in nontuberculous mycobacterial infection;Clinica Chimica Acta;2025-01

2. What is New in Augmented Renal Clearance in Septic Patients?;Current Infectious Disease Reports;2023-10-26

3. Therapeutic Drug Monitoring of Amikacin in Neutropenic Oncology Patients;Antibiotics;2023-02-11

4. Amikacin pharmacokinetics in elderly patients with severe infections;European Journal of Pharmaceutical Sciences;2022-08

5. Recommended Antibiotic Dosage Regimens in Critically Ill Patients with Augmented Renal Clearance: A Systematic Review;International Journal of Antimicrobial Agents;2022-05